Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Autor:	Ehrhardt MJ; Department of Oncology and Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: matthew.ehrhardt@stjude.org., Leerink JM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands., Mulder RL; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Mavinkurve-Groothuis A; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Kok W; Department of Clinical and Experimental Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands., Nohria A; Department of Internal Medicine, Division of Cardiology, Brigham and Women's Hospital, Boston, MA, USA., Nathan PC; Department of Pediatrics, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada., Merkx R; Department of Medical Imaging, Radboud University Medical Center, Nijmegen, Netherlands., de Baat E; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Asogwa OA; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Skinner R; Department of Paediatric and Adolescent Haematology and Oncology, Great North Children's Hospital, Newcastle upon Tyne, UK; Newcastle University Centre for Cancer, Newcastle upon Tyne, UK., Wallace H; Department of haematology and oncology, Royal Hospital for Sick Children and Young People, Edinburgh, UK; University of Edinburgh, Edinburgh, UK., Lieke Feijen EAM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., de Ville de Goyet M; Pediatric Hematology & Oncology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium; Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium., Prasad M; Division of Paediatric Oncology, Tata Memorial Hospital, Mumbai, India; Homi Bhabha National Institute, Mumbai, India., Bárdi E; Hematoonokological and Immunological Outpatient Department, St Anna Children's Hospital, Vienna, Austria; Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria., Pavasovic V; Department Paediatric Haemato-Oncology, Great Ormond Street Hospital for Children NHS Trust, London, UK., van der Pal H; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Fresneau B; Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France., Demoor-Goldschmidt C; Radiation Epidemiology Team, INSERM U1018, Paris-Sud XI University, Centre for Research in Epidemiology and Population Health, Cancer & Radiations Group, Gustave Roussy, Villejuif, France; Department of Pediatric Hematology and Oncology, CHU Angers, Angers, France; Department of Radiotherapy and Supportive care department, François Baclesse Center, Caen, France., Hennewig U; Department of Pediatric Hematology and Oncology, University Hospital of Giessen and Marburg, Giessen, Germany., Steinberger J; Department of Pediatric Cardiology, University of Minnesota School of Medicine, Minneapolis, MN, USA., Plummer C; Department of Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Chen MH; Department of Cardiology and Pediatrics, Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, MA, USA., Teske AJ; Department of Cardiology, Division of Heart and Lung, University Medical Center Utrecht, Utrecht, Netherlands., Haddy N; Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Radiation Epidemiology Team, INSERM U1018, Paris-Sud XI University, Centre for Research in Epidemiology and Population Health, Cancer & Radiations Group, Gustave Roussy, Villejuif, France., van Dalen EC; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands., Constine LS; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA., Chow EJ; Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA; Division of Clinical Research and Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA., Levitt G; Department of Oncology, Great Ormond Street Hospital for Children NHS Trust, London, UK., Hudson MM; Department of Oncology and Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA., Kremer LCM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Emma Children's Hospital, Amsterdam UMC, Amsterdam, Netherlands., Armenian SH; Department of Pediatrics and Department of Population Sciences, City of Hope National Medical Center, Duarte, CA, USA.
Jazyk:	angličtina
Zdroj:	The Lancet. Oncology [Lancet Oncol] 2023 Mar; Vol. 24 (3), pp. e108-e120. Date of Electronic Publication: 2023 Feb 14.
DOI:	10.1016/S1470-2045(23)00012-8
Abstrakt:	Survivors of childhood, adolescent, and young adult cancer, previously treated with anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was exposed, are at increased risk of cardiomyopathy. Symptomatic cardiomyopathy is typically preceded by a series of gradually progressive, asymptomatic changes in structure and function of the heart that can be ameliorated with treatment, prompting specialist organisations to endorse guidelines on cardiac surveillance in at-risk survivors of cancer. In 2015, the International Late Effects of Childhood Cancer Guideline Harmonization Group compiled these guidelines into a uniform set of recommendations applicable to a broad spectrum of clinical environments with varying resource availabilities. Since then, additional studies have provided insight into dose thresholds associated with a risk of asymptomatic and symptomatic cardiomyopathy, have characterised risk over time, and have established the cost-effectiveness of different surveillance strategies. This systematic Review and guideline provides updated recommendations based on the evidence published up to September, 2020. Competing Interests: Declaration of interests AN reports research support from Amgen; a research contract with Bristol Myers Squibb; consulting fees from AstraZeneca, Boehringer Ingelheim, and Bantam Pharmaceuticals; and participation on a data safety monitoring board for Takeda Oncology. CP reports personal honoraria and expenses for presentation at education meetings from Amgen, Incyte, Ipsen, Novartis, and Servier. LSC reports grant funding from the University of Alabama for the Children's Oncology Group Guidelines, payment or honoraria for lectures or presentations from the American Society of Hematology and the University of Miami, and participation in the National Cancer Institute PDQ Pediatric Oncology Board. EJC is the Principal Investigator on a research grant to his institution from Abbott Laboratories. All other authors declare no competing interests. (Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu